Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7771649 | 0.84 | GABRA1 (0.43) | GABRA1GABRB2GABRG2GABRB3LPAR1 | |
| SCHEMBL487530 | 0.83 | GABRA1 (0.41) | GABRA1GABRB2GABRG2GABRB3LPAR1 | |
| SCHEMBL2889829 | 0.83 | PDK2 (0.36) | GABRA1GABRB2LMNAHPGDTSHR | |
| SCHEMBL23489760 | 0.83 | PDK2 (0.36) | GABRA1GABRB2LMNAHPGDTSHR | |
| SCHEMBL4606173 | 0.83 | CYP2D6 (0.38) | CYP1A2CYP3A4LMNASLC6A2KMT2A | |
| SCHEMBL10178554 | 0.82 | TSHR (0.52) | GABRA1GABRB2TSHRL3MBTL1PDK2 | |
| SCHEMBL13535483 | 0.81 | GABRA1 (0.34) | GABRA1GABRB2GABRG2GABRB3LPAR1 | |
| SCHEMBL8520287 | 0.81 | GABRA1 (0.40) | GABRA1GABRB2GABRG2GABRB3LPAR1 | |
| SCHEMBL12863292 | 0.81 | GABRA1 (0.40) | GABRA1GABRB2GABRG2GABRB3LPAR1 | |
| SCHEMBL711281 | 0.81 | GABRA1 (0.40) | GABRA1GABRB2GABRG2GABRB3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| CN-114292828-A | Tetrameric alpha/beta hydrolase variants with improved temperature stability and methods of use and production thereof | 爱尔伯股份公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| WO-2021064677-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-04-08 | — | — | WO | disclosed |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120328691-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2012-12-27 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-02-09 | — | — | US | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100099875-A1 | NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS | PHOSPHOENIX SARL (FR) | 2010-04-22 | — | — | US | disclosed |
| US-20080312319-A1 | Modulation of Bacterial Quorum Sensing with Synthetic Ligands | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | GABRA1 194/4885GABRB2 133/4885GABRG2 272/4885 |
| US-20100099875-A1 | NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS | PNP, NANP, PHOSPHO1 | GABRA1 3000/4885GABRB2 3371/4885GABRG2 3026/4885 |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | GABRA1 194/4885GABRB2 133/4885GABRG2 272/4885 |
| US-20080312319-A1 | Modulation of Bacterial Quorum Sensing with Synthetic Ligands | AHCYL1, EBPL, AIP | GABRA1 1279/4885GABRB2 2443/4885GABRG2 1904/4885 |
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | GABRA1 879/4885GABRB2 632/4885GABRG2 727/4885 |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC1R, MC3R, MC2R | GABRA1 252/4885GABRB2 179/4885GABRG2 189/4885 |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | GABRA1 2483/4885GABRB2 2471/4885GABRG2 2945/4885 |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | GABRA1 194/4885GABRB2 133/4885GABRG2 272/4885 |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | GABRA1 394/4885GABRB2 183/4885GABRG2 365/4885 |
| US-20120328691-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MAPK15, CDK15, MAPKAPK5 | GABRA1 4431/4885GABRB2 4449/4885GABRG2 4101/4885 |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | GABRA1 1083/4885GABRB2 1515/4885GABRG2 1917/4885 |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | GABRA1 394/4885GABRB2 183/4885GABRG2 365/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | GABRA1 1072/4885GABRB2 564/4885GABRG2 1222/4885 |
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | GABRA1 194/4885GABRB2 133/4885GABRG2 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.